Picture EBD Group Biotech Showcase 2025 San Francisco BTS25 650x100px

Financing › Details

Abivax–SEVERAL: credit, 202107– convertible bonds €25m at 6% interest/year

	Period	2021-07-23
	Money taker	Abivax S.A. (Euronext Paris: ABVX)
	Group	Abivax (Group)
	Money source	SEVERAL
	Product	obefazimod (ABX464)
	Product 2	investment banking
	Index term	Abivax–SEVERAL: investment, 202107 capital increase €60m with 3% discount with 1.97m shares at €30.55/share
	Source	Abivax S.A.. (7/23/21). "Press Release: Abivax Announces the Pricing of Its Oversubscribed Capital Increase of EUR 60M and Convertible Bonds of EUR 25M, Totaling EUR 85M New Financing". Paris.

Record changed: 2024-12-20

Picture EBD Group Biotech Showcase 2025 San Francisco BTS25 650x200px

More documents for Abivax (Group)

[1] Abivax S.A.. (10/24/23). "Press Release: Abivax Announces Closing of its Initial Public Offering on the Nasdaq Global Market". Paris....
[2] Abivax S.A.. (10/20/23). "Press Release: Abivax Announces the Pricing of Its Initial Public Offering on the Nasdaq Global Market". Paris....
[3] Abivax S.A.. (9/29/23). "Press Release: Abivax Files Registration Statement for Proposed Initial Public Offering in the United States". Paris....
[4] Abivax S.A.. (8/23/23). "Press Release: Abivax Appoints Patrick Malloy as Senior Vice President Investor Relations". Paris....
[5] Abivax S.A.. (8/21/23). "Press Release: Abivax Secures Up to EUR 150M from Two Structured Debt Financing Transactions". Paris....
[6] Abivax S.A.. (7/11/23). "Press Release: Abivax Announces the Appointment of June Lee, M.D. and Troy Ignelzi as Members of the Board of Directors". Paris....
[7] Abivax S.A.. (9/2/22). "Press Release: Abivax Announces Successful Oversubscribed EUR 49.2M Cross-over Financing with Top-tier US and European Biotech Investors [not for US]". Paris....
[8] Abivax S.A.. (7/23/21). "Press Release: Abivax Announces the Pricing of Its Oversubscribed Capital Increase of EUR 60M and Convertible Bonds of EUR 25M, Totaling EUR 85M New Financing". Paris....
[9] Abivax S.A.. (6/23/21). "Press Release: Abivax Reports Excellent Phase 2a Clinical Safety and Efficacy Results with 50mg ABX464 in Rheumatoid Arthritis". Paris....
[10] Abivax S.A.. (3/14/19). "Press Release: Abivax 2018 Financial Results and Operations Update". Paris....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]